The Manufacturers Life Insurance Company Sells 137,655 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

The Manufacturers Life Insurance Company lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 41.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 191,382 shares of the biopharmaceutical company’s stock after selling 137,655 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.15% of Alnylam Pharmaceuticals worth $52,636,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ALNY. Ashton Thomas Private Wealth LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at $26,000. Huntington National Bank lifted its stake in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares during the period. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth about $29,000. Washington Trust Advisors Inc. purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth about $42,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth about $45,000. Institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Pushkal Garg sold 1,682 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at $4,381,357.86. The trade was a 8.79 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,370 shares of company stock valued at $2,100,703 in the last 90 days. 1.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Wells Fargo & Company increased their price target on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. Barclays increased their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Finally, HC Wainwright reissued a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $253.74 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company’s 50 day moving average is $271.93 and its 200 day moving average is $240.19. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company has a market cap of $32.73 billion, a PE ratio of -96.85 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.15 earnings per share. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.